ENDOCRINE TESTING PRODUCT MARKET ANALYSIS

Endocrine systems consist of various glands, which release specific hormones into the bloodstream in human body. These hormones are carried with the blood throughout the body and control various functions of the body such as metabolism, growth and development, reproduction, stimuli response, and homeostasis. The endocrine system consists of various glands such as hypothalamus, pancreas, adrenal glands, thyroid, and pituitary gland. The hormones secreted by these glands are used to maintain various biological functions in the human system. Therefore, an imbalance in the concentrations of hormones in human system may lead to certain conditions, like weight gain, muscle weakness etc. Endocrine testing consists of diagnosis of concentration of endocrine hormones in human system such as estradiol, testosterone, progesterone, insulin, thyroid, luteinizing, cortisol DHEA-S, prolactin, follicle stimulating hormone, human chorionic gonadotropin, and hormone. The testing helps to understand the concentration of specific hormones in the blood.

Global Endocrine Testing Products Market - Impact of the Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic is expected to increase the growth of the global endocrine testing products market, owing to the increase in the number of patients suffering from hormonal conditions, post COVID-19 infection. For instance, according to the article published in the Frontiers in Nutrition Journal, published in March 2021, there has been increase in the number of patients suffering from hormonal imbalance post-COVID-19 infection. This can be observed as the number of patients visiting the hospitals for the treatment of hormonal condition is increasing. According to the same source, there has been an impact on the pathophysiology and management of diabetes (both outpatient and inpatient) as well as pituitary, adrenal, thyroid, bone, and gonadal function, in post COVID-19 patients.

COVID-19 has completely altered both the clinical practice and the social relationships. Many organs and biological systems are affected by SARS-CoV-2 infection, either directly from virus damage or indirectly through effects that can have systemic consequences. The endocrine system is not only an exception, but its involvement in COVID-19 is so significant that an ‘endocrine phenotype’ of COVID-19 has gradually gained clinical relevance. For instance, according to an article published in Endocrine journal, May 2021, diabetes plays a significant role in this phenotype because it is one of the most common comorbidities associated with COVID-19 severity and mortality. Careful management, including treatment modifications, may be required to protect patients suffering from endocrine diseases from the most dangerous consequences of COVID-19, not only in those with known diabetes or those hospitalized with COVID-19, but also in those with SARS-CoV-2 induced newly onset diabetes.

Moreover, according to the same source, lack of vitamin D, hypocalcaemia, and vertebral fractures have also emerged as common findings in the hospitalized COVID-19 population, which may interfere with their treatment. Additionally, in patients with adrenal insufficiency, glucocorticoid doses may need to be adjusted right away.

The global endocrine testing products market is estimated to be valued at US$ 11,695.7 Mn in 2022 and is expected to exhibit a CAGR of 8.9% over the forecast period (2022-2030)  

Figure 1: Global Endocrine Testing Products Market Share, (%), Analysis, By Product, 2022

To learn more about this report, request a free sample copy

Market players are indulged in inorganic activities such as acquisition, in order to enhance company’s product portfolio. This is expected to drive growth of the global endocrine testing products market over the forecast period.

Market players are engaged in the inorganic activities such as acquisitions and this is expected to drive growth of the global endocrine testing products market over the forecast period. For instance, in March 2021, Roche, a Swiss multinational healthcare company and GenMark Diagnostics, a molecular diagnostics company, announced a definitive merger agreement in which Roche will fully acquire GenMark Diagnostics for US$ 24.05 per share in an all-cash transaction. As a result of this acquisition, GenMark's syndromic panel testing portfolio will complement Roche's current molecular diagnostics portfolio.

Increasing product launches by the market players is expected to drive the growth of the global endocrine testing products market over the forecast period

Product launches by the market players is expected to drive growth of the global endocrine testing products market over the forecast period. For instance, in March 2020, Agilent Technologies Inc., an American analytical instrumentation, officially launched the Agilent K6460S Clinical Edition TQ LC/MS system, which is intended to improve in vitro diagnostic workflows in clinical laboratories. The K6460S, Agilent's next-generation clinical edition triple quadrupole liquid chromatography-mass spectrometry (LC/MS) system, is classified as a Class I medical device by the U.S. Food and Drug Administration. Moreover, in June 2019, Abbott Laboratories, an American multinational medical devices and health care company, launched Afinion HbA1c Dx assay to be operated on Afinion 2 Analyzer and Afinion AS100 Analyzer for the diagnosis of diabetes and identification of patients at the risk of developing diabetes.

Global Endocrine Testing Products Market – Restraints

Most of the underdeveloped regions cannot afford new technologies for endocrine testing, which is expected to hamper the growth of the global endocrine testing products market. For instance, the technological advancements in diagnostic testing systems and test kits have resulted in high cost of these products. Test kits for endocrine testing alone cost anywhere between US$ 100 to US$ 700-800. Several countries in emerging regions such as Latin America, Asia Pacific, Middle East, and Africa are not in a position to afford implementation of advanced technologies (such as use of monoclonal and polyclonal antibodies in diagnostic practice/for assay development) in clinical practice. Moreover, owing to underdeveloped healthcare infrastructure, conventional diagnostic testing techniques are performed in several countries of these regions, especially in North and Central Africa and Asia Pacific. These factors are expected to restrain the growth of the global endocrine testing products market growth over the forecast period.

Global Endocrine Testing Products Market – Regional Analysis

On the basis of region, global endocrine testing products market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa

Among regions, North America endocrine testing products market is expected to hold a dominant position during the forecast period, owing to the inorganic strategies such as partnerships. For instance, in 2020, Ro, the healthcare technology company, and Quest Diagnostics, a manufacturer of diagnostic products, entered into strategic partnership to add diagnostic capabilities and lab testing facilities to Ro's primary care platform. This partnership will support Ro’s expansion in the U.S. by providing solutions for diagnosis, treatment, and management of chronic and complex medical conditions using the platform.

Furthermore, Europe is also estimated to witness significant growth in the global endocrine testing products market, owing to increasing research and development activities by the organizations. European Cluster to improve Identification of endocrine disruptors (EURION Cluster) has eight research projects, which are focusing on ‘New Testing and Screening Methods to Identify Endocrine Disrupting Chemicals’. The projects received a funding of US$ 55.9 million from the EU Horizon 2020 Research and Innovation Program.

Figure 2: Global Endocrine Testing Products Market (US$ Mn), by Region, 2022

To learn more about this report, request a free sample copy

Global Endocrine Testing Products Market – Competitive Landscape

Major players operating in the global endocrine testing products market include F. Hoffmann-la Roche Ag, Abbott Laboratories, Agilent Technologies, BioMerieux S.A., Bio-Rad Laboratories, Inc., Siemens Healthineers, Danaher Corporation, DiaSorin S.p.A., Immunodiagnostic Systems, Laboratory Corporation of America Holdings (LabCorp),  Fujirebio, Inc., Thermo Fisher Scientific Inc., Quest Diagnostics, Sysmex Corporation, MP Biomedicals, Ortho Clinical Diagnostics, and Meridian Life Science, Inc.